Stock Events

Stock Events

Kala Bio 

€0.14
54
-€0.02-9.91% Thursday 06:50

Statistics

Day High
0.14
Day Low
0.14
52W High
16.99
52W Low
0.13
Volume
-
Avg. Volume
-
Mkt Cap
1.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
Next
-4.41
-2.99
-1.58
-0.17
Expected EPS
-0.17
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-73.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 27F0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the ophthalmology space with treatments for eye diseases, directly competing with Kala's eye care products.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a range of eye care medications, including treatments for conditions that Kala Bio targets, making them a direct competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology market, competing with Kala Bio's eye care solutions.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant portfolio in eye health, competing in the same market as Kala Bio.
Biogen
BIIB
Mkt Cap22.63B
Biogen has a focus on specialty care and biologics that could compete with Kala Bio's treatments in certain niche markets.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is a biotechnology company focused on the development of gene therapies for eye diseases, directly competing with Kala Bio's approach to eye care.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, while primarily known for its work in antiviral drugs, has ventured into other therapeutic areas that could potentially compete with Kala Bio's niche markets.

About

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Show more...
CEO
Dr. R. Kim Brazzell Ph.D.
Employees
38
Country
US
ISIN
US4831192020
WKN
000A3DWPS

Listings

XNAS
US
KALA
LSE
GB
0JQ2.LSE
BOATS
BOATS
KALA.BOATS
F
DE
27F0.F

0 Comments

Share your thoughts

FAQ

What is Kala Bio stock price today?▼
The current price of 27F0.F is €0.14 EUR — it has decreased by -9.91% in the past 24 hours. Watch Kala Bio stock price performance more closely on the chart.
What is Kala Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kala Bio stocks are traded under the ticker 27F0.F.
Is Kala Bio stock price growing?▼
27F0.F stock has fallen by -14.75% compared to the previous week, the month change is a -58.64% fall, over the last year Kala Bio has showed a -96.8% decrease.
What is Kala Bio market cap?▼
Today Kala Bio has the market capitalization of 1.12M
When is the next Kala Bio earnings date?▼
Kala Bio is going to release the next earnings report on May 19, 2026.
What is Kala Bio revenue for the last year?▼
Kala Bio revenue for the last year amounts to 0 EUR.
What is Kala Bio net income for the last year?▼
27F0.F net income for the last year is -73.02M EUR.
How many employees does Kala Bio have?▼
As of April 03, 2026, the company has 38 employees.
In which sector is Kala Bio located?▼
Kala Bio operates in the Health Care sector.
When did Kala Bio complete a stock split?▼
The last stock split for Kala Bio was on October 21, 2022 with a ratio of 1:50.
Where is Kala Bio headquartered?▼
Kala Bio is headquartered in Arlington, US.